Pozen Inc. (POZN)

[Topgun21]

Run POZN!!!

Tim

[Topgun21]

Exactly. I still go with them getting buy out offer this year!!!

We shall see!!

Tim

[Tina]

POZEN Announces Election of Neal F. Fowler to the Board of Directors
Jun 15, 2010 6:30:00 AM
Copyright Business Wire 2010


CHAPEL HILL, N.C.--(BUSINESS WIRE)-- POZEN Inc. (NASDAQ: POZN), today announced the election of Neal F. Fowler to its Board of Directors at the Annual Meeting of Shareholders held on June 10, 2010. Mr. Fowler is Chief Executive Officer of Liquidia Technologies, Inc. Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE(R) (infliximab). Prior to Centocor, Mr. Fowler was President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, where he doubled sales of the cardiovascular business unit over a three-year period. Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill.

Dr. John R. Plachetka, POZEN's Chairman, President and Chief Executive Officer said, "We are pleased to welcome Neal to the POZEN Board of Directors. His years of pharmaceutical experience will not only compliment, but will also expand the strength and capabilities of our board."

About POZEN

POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st Century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers.

The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.




Source: POZEN Inc.


----------------------------------------------
POZEN Inc.
Bill Hodges
919-913-1030
Chief Financial Officer

[$to©k_Pi©ker™]

IMO, this is a very, very, very good investment. In the long run, this will do very well.

If your not patient, then it is not a good investment.

[XrayGuy85]

You still coming here to grief everyone?

Waste of time IMO

[invest2win]

You guys still hoping for a miracle here. Or maybe another approval God forbid. We wouldn't want this P&D to sink again. What a POS!

[DAD2]

Looks like this is ready to move into positive territory IMO.


http://stockcharts.com/h-sc/ui?s=POZN&p=D&yr=0&mn=3&dy=0&id=p32262285736

[Neil_B]

I got note from POZN to contact Astra. Since Astra is not responding back, I have asked themn for a relevent contact there. Let's see

[Neil_B]

I also sent the question to POZN. Let's see what we hear back

[richard.w]

Could this finally be the bottom? It would be a great place for a turnaround on the chart.

[Neil_B]

Hello. I logged an email request will astra. They haven't replied yet. I didn't try pozn because they would have probably directed me back to astra

[luvn socal]

Well, have you heard anything Neil?

[richard.w]

Listen Live at 3pm ET today
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=121701&eventID=3107530

POZEN Inc. at Jefferies Global Life Sciences Conference
Tuesday, June 8, 2010 3:00 p.m. ET
Listen to the Webcast in Windows Media Player Listen to the Webcast in Real Player

Event Details
Title POZEN Inc. at Jefferies Global Life Sciences Conference
Date and Time Tuesday, June 8, 2010 3:00 p.m. ET
Duration 45 Minutes
Location New York, NY

[Neil_B]

I will put in an inquiry with POZN and AZN to see if they can validate this.

[$pmlg]

yes, more than happy on MY board...link below my siggy...
or

http://investorshub.advfn.com/boards/board.aspx?board_id=17524

[luvn socal]

here is a link to a post from FDA Plays:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=50797042

Not informative just a statement

[luvn socal]

i will see if I can find it...it had to do with a talk the CEO gave on a conference call.

[Neil_B]

where did you read about the holding of EU approval, link please.

[luvn socal]

did you know about this? It was posted on the FDA Plays and Sheff's board.

[Topgun21]

Hmm, interesting!!

Tim

[luvn socal]

That would be amazing Tim and very doable...did you see that they are holding off the possible/probable EU approval till 1Q 2011? What is to be made of that?

[Topgun21]

POZN..

DEBT FREE!!!

Royalty payments = Command a High price per share!!

All in my humble opinion!!

$15/share please!!!

Tim
POZN

[$to©k_Pi©ker™]

Very highly possible

[Topgun21]

$15 share buyout... My guess. We shall see!!

Tim

[Neil_B]

Details about FDA delay of Astrazeneca's drug, which is fuelling the buyout possibility

http://www.delawareonline.com/article/20100602/BUSINESS/6020308

[zigzagman]

Pozen Moves Higher as Analyst Suggests Buyout Possibility:

The tickerspy.com Staff, On Wednesday June 2, 2010, 11:56 am EDT

http://finance.yahoo.com/news/Pozen-Moves-Higher-as-Analyst-indie-2174207811.html?x=0&.v=1

Shares of POZEN (NASDAQ: POZN) are higher today after analyst Brean Murray suggested that Pozen has become an even more attractive acquisition target following the firm's receipt of a $20 million milestone payment from AstraZeneca (NYSE: AZN) for the FDA's approval of arthritis and gastric ulcer drug Vimovo. Brean Murray belives that, following the FDA delaying approval for AstraZenaca's ulcer treatment Axanum, the pharma giant may want to snap up the $225-millions biotech.

As a whole, the Biotechnology Stocks Index is ahead by 2% today, led by Amgen (NASDAQ: AMGN), Protalix BioTherapeutics (AMEX: PLX), and Affymax (NASDAQ: AFFY).

Sector giants, Gilead Sciences (NASDAQ: GILD) and Celgene (NASDAQ: CELG), are both near unchanged. Impax Laboratories (NASDAQ: IPXL) is a notable loser, slipping by -3%, while names like Repligen (NASDAQ: RGEN), United Therapeutics (NASDAQ: UTHR), vaccine player Novavax (NASDAQ: NVAX), and molecular drug company Exelixis (NASDAQ: EXEL), are participating in the rally today, all moving up by 3% or more.

There also might be more upside for Pozen from here. According to the company press release, an additional $25 million milestone payment will be made to Pozen if Vimovo receives marketing approval in a major "ex-U.S." market. In total, Pozen could be in line to receive a total of $260 million (including milestone and sales royalties) from AstraZeneca.

It will be interesting to see where the stocks in the biotech segment go from here...

[$pmlg]

charts are automatically update...good question.
yes, one can add new content to post, and link back to previous post, or by replying to it.

btw...my post had shown a turning point, bottom.

[barefootrunner]

POZN definitely had a solid day yesterday. Not sure if you saw the Brean Murray buyout speculation - http://finance.yahoo.com/news/Pozen-Moves-Higher-as-Analyst-indie-2174207811.html?x=0&.v=1

I definitely think POZN is a solid company and is still undervalued at these levels. I am currently loaded with ASCO plays - DCTH, SNSS, PCYC - but will be keeping this on a very close watch.

If POZN can break above the 100DMA, it could run back to the high 9's assuming the bears stay away in the overall markets.

[North Coast]

How do you have a post dated May 27 with a chart from June 2nd?

Are you able to change the content of the post and the date stays the same?

[North Coast]

What is your opinion now?

I've been following $heff recently and wonder if he is getting back in soon as well?

[North Coast]

Chart looks great here after the recent pounding and Wednesday's reversal day at the 200 day SMA.

It was a stop-shopping that took this baby down on announcement day, not bad news. Fear, panic and confusion followed.

But the worst looks priced in now and the big money has filled up the tanks.

Away we go again.

[Tina]

Maybe some really bad news will send us over the top :)

lol

[DAD2]

Nice .47 gain on no news, nice suprise.

[invest2win]

I see it hasn't stopped stocks like VVUS. Just another excuse. They will all run out eventually.

[XrayGuy85]

The whole market is down right now. The uncertainty in Europe and the Gulf oil crisis are making a lot of people nervous.

Once things settle down, we may see an upswing.

[invest2win]

I moved on a long time ago. Save the pump job for the newbies please.
We were all expecting at least $18.00 after the approval. Many here can attest to that. Including Mr. Sheff himself.SOMX did just fine after their approval. There is only so many excuses you can make for a stock.

[DAD2]

Seems funny that the price from $11-$12 was only 28 days ago, most stocks have gotten killed alot worse in recent days not sure what you are expecting $50+ if so your right you should move on IMO.

[barefootrunner]

I am quite surprised as well. Sold after the approval and have been waiting to get back in, but this really seems to want to test the 200DMA. One more bearish market day and its there.

Still way undervalued at this point, particularly given the FLE of EU approval and milestone payments from AZN.

[$pmlg]

POZN 7.00 7.20 buck is the turning point...hold area, rebuy imo..

never thought this would be it...

[invest2win]

I think it is time to admit that this stock just stinks period. A FDA Approval, A 20 Million dollar payment and still it goes nowhere.

It made its run before the approval and we have to accept that fact. It may never run that high again. For those getting in at a lower average that is a different story.

There's nothing to do but average down and keep selling to recoup money for those that bought in the high 10's, 11's, before the approval. Just my opinion but sometimes you just have to take your losses and move on to the next one.

[skibum2k]

Remember, with this company expect the UNEXPECTED!

[richard.w]

Tomorrow should be interesting!

[DAD2]

Nice payment !!!!

That will beef up the balance sheet.

[skibum2k]

THANKS!!

[zigzagman]

This is very good news indeed...

[stocktrader001]

i got this in my mail about 15 min ago.

[skibum2k]

Nice STOCKFREAK! What time was this PR released?

[stocktrader001]

POZEN Announces Receipt of $20 Million Milestone Payment from AstraZeneca

CHAPEL HILL, N.C., May 25, 2010 (BUSINESS WIRE) --POZEN Inc. (NASDAQ: POZN), announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration (FDA) approval of VIMOVO(TM) (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application (IND) and New Drug Application (NDA) for VIMOVO to AstraZeneca over the next few weeks.

An additional $25 million milestone will be payable if VIMOVO receives marketing approval in a major ex-U.S. market (including pricing and reimbursement approval). Under the terms of the agreement, AstraZeneca will pay POZEN royalties on net sales of VIMOVO worldwide and POZEN could receive up to $260 million in sales performance milestones, if certain sales thresholds are achieved. AstraZeneca has responsibility for all commercialization activities.

VIMOVO is approved for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is a fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and immediate-release esomeprazole, a proton pump inhibitor.

The FDA approval of VIMOVO marks the second time in just two years that POZEN has received an FDA approval for a new product, which required the demonstration of superiority over an active comparator in two large pivotal Phase 3 trials. This makes POZEN a standout among biotech and specialty pharmaceutical companies, one of only a very few that have ever earned FDA approval for a self-invented product, and one of an even smaller number of companies to do this twice.

About POZEN

POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st Century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers.

The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.

http://phx.corporate-ir.net/phoenix.zhtml?c=121701&p=irol-NRText&ID=1431018&highlight=

[geodan]

Thanks Xray. I just entered the field with Spock like XRF analyzer for prospecting, jewelry etc.

Thanks for opinion, I might nibble to average down myself. Chart looks washed out.

What did you think of my attempt at being a analyst (report)?

Cheers

[XrayGuy85]

I'd say July has a fairly good chance at getting to 12.5 but don't quote me on that haha.

I'm holding through EMEA approval, which I hope will come by July and ought to send the PPS upwards (emphasis on ought to. As we've all seen, approval isn't necessarily a guaranteed PPS pusher)




For my handle, I just take x-rays. That's all :D